Chemomab Therapeutics (CMMB) Competitors $1.02 -0.05 (-4.21%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$1.03 +0.01 (+0.98%) As of 08/1/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMMB vs. CABA, MIST, QNCX, ELUT, BYSI, SRZN, CELU, IMMX, CRVO, and CNTXShould you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Cabaletta Bio (CABA), Milestone Pharmaceuticals (MIST), Quince Therapeutics (QNCX), Elutia (ELUT), BeyondSpring (BYSI), Surrozen (SRZN), Celularity (CELU), Immix Biopharma (IMMX), CervoMed (CRVO), and Context Therapeutics (CNTX). These companies are all part of the "pharmaceutical products" industry. Chemomab Therapeutics vs. Its Competitors Cabaletta Bio Milestone Pharmaceuticals Quince Therapeutics Elutia BeyondSpring Surrozen Celularity Immix Biopharma CervoMed Context Therapeutics Chemomab Therapeutics (NASDAQ:CMMB) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends. Does the media prefer CMMB or CABA? In the previous week, Chemomab Therapeutics had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 1 mentions for Chemomab Therapeutics and 0 mentions for Cabaletta Bio. Chemomab Therapeutics' average media sentiment score of 0.99 beat Cabaletta Bio's score of 0.00 indicating that Chemomab Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Chemomab Therapeutics Positive Cabaletta Bio Neutral Which has preferable valuation and earnings, CMMB or CABA? Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChemomab TherapeuticsN/AN/A-$13.94M-$0.76-1.35Cabaletta BioN/AN/A-$115.86M-$2.54-0.57 Is CMMB or CABA more profitable? Cabaletta Bio's return on equity of -78.29% beat Chemomab Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Chemomab TherapeuticsN/A -106.70% -82.18% Cabaletta Bio N/A -78.29%-65.68% Which has more risk and volatility, CMMB or CABA? Chemomab Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 2.74, suggesting that its stock price is 174% more volatile than the S&P 500. Do insiders and institutionals hold more shares of CMMB or CABA? 46.1% of Chemomab Therapeutics shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 11.3% of Cabaletta Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend CMMB or CABA? Chemomab Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 729.27%. Cabaletta Bio has a consensus price target of $14.43, suggesting a potential upside of 901.98%. Given Cabaletta Bio's higher possible upside, analysts clearly believe Cabaletta Bio is more favorable than Chemomab Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Cabaletta Bio 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryCabaletta Bio beats Chemomab Therapeutics on 7 of the 13 factors compared between the two stocks. Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMMB vs. The Competition Export to ExcelMetricChemomab TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.18M$2.99B$5.48B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-1.3517.7428.8623.83Price / SalesN/A178.75371.7266.14Price / CashN/A41.9535.4557.96Price / Book1.428.508.275.54Net Income-$13.94M-$55.06M$3.25B$259.28M7 Day Performance-5.96%-3.99%-3.74%-4.67%1 Month Performance-10.87%9.58%4.28%4.37%1 Year Performance-1.44%6.70%25.87%17.91% Chemomab Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMMBChemomab Therapeutics2.9438 of 5 stars$1.03-4.2%$8.50+729.3%-11.6%$20.18MN/A-1.3520CABACabaletta Bio1.8014 of 5 stars$1.63-3.8%$14.43+787.9%-79.1%$82.46MN/A-0.6450Positive NewsUpcoming EarningsMISTMilestone Pharmaceuticals1.8266 of 5 stars$1.52-2.3%$7.00+362.0%+2.9%$81.00MN/A-1.9430Positive NewsUpcoming EarningsShort Interest ↑QNCXQuince Therapeutics2.4373 of 5 stars$1.78-1.4%$8.00+350.7%+125.9%$80.71MN/A-1.2860Negative NewsShort Interest ↑ELUTElutia3.452 of 5 stars$1.95-1.3%$8.00+311.3%-40.4%$79.98M$24.38M-1.01180News CoverageUpcoming EarningsGap DownBYSIBeyondSpringN/A$1.98+2.9%N/A+6.7%$79.63M$1.75M0.0080SRZNSurrozen1.8365 of 5 stars$8.87-0.9%$38.50+334.0%+36.1%$78.71M$10.65M-0.3780Gap DownCELUCelularity0.2161 of 5 stars$3.24-1.5%N/A-1.0%$78.08M$54.22M-1.23220News CoverageUpcoming EarningsAnalyst UpgradeIMMXImmix Biopharma2.6353 of 5 stars$2.74+0.7%$7.00+155.5%+27.4%$76.39MN/A-3.919News CoveragePositive NewsCRVOCervoMed2.6636 of 5 stars$8.79+1.4%$20.50+133.2%-28.6%$76.31MN/A-4.024Upcoming EarningsAnalyst ForecastGap DownCNTXContext Therapeutics2.5921 of 5 stars$0.85-0.4%$5.50+549.4%-68.2%$75.98MN/A-2.737News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies CABA Competitors MIST Competitors QNCX Competitors ELUT Competitors BYSI Competitors SRZN Competitors CELU Competitors IMMX Competitors CRVO Competitors CNTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMMB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMMB Stock Alerts